A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED)

A Randomized, Double-Blind, Active-Comparator-Controlled 5-Day Trial of the Effect of Etoricoxib 120 mg Versus Indomethacin 150 mg in the Treatment of Acute Gout

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00142558

Enrollment

180

Registered

2005-09-02

Start date

2005-01-01

Completion date

2005-05-01

Last updated

2024-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Gout

Keywords

Arcoxia

Brief summary

A study to evaluate the effects of etoricoxib and indomethacin in the treatment of acute gout.

Interventions

DRUGMK0663; etoricoxib / Duration of Treatment: 5 Days

DRUGComparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Males or females at least 18 years of age who have acute gout.

Design outcomes

Primary

Measure	Time frame
Patient assessment of pain (0- to 4- Likert scale)	—

Secondary

Measure	Time frame
Patient Global Assessment of Response to Therapy (0- to 4- point scale)	—
Investigator Global Assessment of Response to Therapy (0- to 4- point scale)	—
Tenderness of the study joint (0- to 3-point scale)	—
Swelling of the study joint (0- to 3-point scale)	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026